- Home
- RDN vs MRUS Comparison
RDN vs MRUS Comparison
Compare RDN & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDN
- MRUS
- Stock Information
- Founded
- RDN 1977
- MRUS 2003
- Country
- RDN United States
- MRUS Netherlands
- Employees
- RDN N/A
- MRUS N/A
- Industry
- RDN Property-Casualty Insurers
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- RDN Finance
- MRUS Health Care
- Exchange
- RDN Nasdaq
- MRUS Nasdaq
- Market Cap
- RDN 4.8B
- MRUS 4.1B
- IPO Year
- RDN 1992
- MRUS 2016
- Fundamental
- Price
- RDN $32.92
- MRUS $65.56
- Analyst Decision
- RDN Hold
- MRUS Strong Buy
- Analyst Count
- RDN 7
- MRUS 13
- Target Price
- RDN $36.86
- MRUS $88.54
- AVG Volume (30 Days)
- RDN 1.2M
- MRUS 712.4K
- Earning Date
- RDN 07-30-2025
- MRUS 08-12-2025
- Dividend Yield
- RDN 3.10%
- MRUS N/A
- EPS Growth
- RDN 3.11
- MRUS N/A
- EPS
- RDN 3.96
- MRUS N/A
- Revenue
- RDN $1,285,836,000.00
- MRUS $54,732,000.00
- Revenue This Year
- RDN N/A
- MRUS $67.27
- Revenue Next Year
- RDN $2.29
- MRUS $0.49
- P/E Ratio
- RDN $8.32
- MRUS N/A
- Revenue Growth
- RDN 0.32
- MRUS 42.77
- 52 Week Low
- RDN $29.32
- MRUS $33.19
- 52 Week High
- RDN $37.63
- MRUS $67.59
- Technical
- Relative Strength Index (RSI)
- RDN 38.61
- MRUS 69.61
- Support Level
- RDN $32.27
- MRUS $64.61
- Resistance Level
- RDN $34.16
- MRUS $67.59
- Average True Range (ATR)
- RDN 0.58
- MRUS 2.32
- MACD
- RDN -0.15
- MRUS 0.30
- Stochastic Oscillator
- RDN 29.55
- MRUS 84.96
About RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one business segment Mortgage Insurance. The Mortgage Insurance segment aggregates, manages, and distributes U.S. mortgage credit risk for the benefit of mortgage lending institutions and mortgage credit investors, through private mortgage insurance on residential first-lien mortgage loans, and also offers other credit risk management solutions, including contract underwriting, to customers. It also provides other mortgage and real estate products and services through Mortgage Conduit, Title, Real Estate Services, and Real Estate Technology businesses.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.